Efficacy of citicoline as an acute stroke treatment

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Citicoline (cytidine-5′-diphosphocholine or CDP-choline) is a precursor essential for the synthesis of phosphatidylcholine, one of the cell membrane components that is degraded during cerebral ischemia to free fatty acids and free radicals. Animal studies suggest that citicoline may protect cell membranes by accelerating resynthesis of phospholipids and suppressing the release of free fatty acids, stabilizing cell membranes, and reducing free radical generation. Numerous experimental stroke studies with citicoline have shown improved outcome and reduced infarct size in both ischemic and hemorrhagic stroke models. Citicoline has been studied worldwide in both ischemic and hemorrhagic clinical stroke with excellent safety and possibly efficacy found in several trials. A meta-analysis of four randomized US clinical citicoline trials concluded that treatment with oral citicoline within the first 24 h after a moderate to severe stroke is safe and increases the probability of complete recovery at 3 months. Citicoline clinical efficacy trials are now continuing outside of the US in both ischemic and hemorrhagic stroke. A citicoline supplement is now available from several sources on the internet.

Original languageEnglish (US)
Pages (from-to)839-846
Number of pages8
JournalExpert Opinion on Pharmacotherapy
Volume10
Issue number5
DOIs
StatePublished - Apr 2009

Fingerprint

Cytidine Diphosphate Choline
Stroke
Cell Membrane
Nonesterified Fatty Acids
Free Radicals
Clinical Trials
Cellular Structures
Brain Ischemia
Phosphatidylcholines
Internet
Meta-Analysis
Phospholipids

Keywords

  • Acute stroke
  • CDP-choline
  • Citicoline
  • Neuroprotection
  • Stroke recovery

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Efficacy of citicoline as an acute stroke treatment. / Clark, Wayne.

In: Expert Opinion on Pharmacotherapy, Vol. 10, No. 5, 04.2009, p. 839-846.

Research output: Contribution to journalArticle

@article{0bb2a30a7ca6457e97ba2b2ec0ecd9f8,
title = "Efficacy of citicoline as an acute stroke treatment",
abstract = "Citicoline (cytidine-5′-diphosphocholine or CDP-choline) is a precursor essential for the synthesis of phosphatidylcholine, one of the cell membrane components that is degraded during cerebral ischemia to free fatty acids and free radicals. Animal studies suggest that citicoline may protect cell membranes by accelerating resynthesis of phospholipids and suppressing the release of free fatty acids, stabilizing cell membranes, and reducing free radical generation. Numerous experimental stroke studies with citicoline have shown improved outcome and reduced infarct size in both ischemic and hemorrhagic stroke models. Citicoline has been studied worldwide in both ischemic and hemorrhagic clinical stroke with excellent safety and possibly efficacy found in several trials. A meta-analysis of four randomized US clinical citicoline trials concluded that treatment with oral citicoline within the first 24 h after a moderate to severe stroke is safe and increases the probability of complete recovery at 3 months. Citicoline clinical efficacy trials are now continuing outside of the US in both ischemic and hemorrhagic stroke. A citicoline supplement is now available from several sources on the internet.",
keywords = "Acute stroke, CDP-choline, Citicoline, Neuroprotection, Stroke recovery",
author = "Wayne Clark",
year = "2009",
month = "4",
doi = "10.1517/14656560902765652",
language = "English (US)",
volume = "10",
pages = "839--846",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Efficacy of citicoline as an acute stroke treatment

AU - Clark, Wayne

PY - 2009/4

Y1 - 2009/4

N2 - Citicoline (cytidine-5′-diphosphocholine or CDP-choline) is a precursor essential for the synthesis of phosphatidylcholine, one of the cell membrane components that is degraded during cerebral ischemia to free fatty acids and free radicals. Animal studies suggest that citicoline may protect cell membranes by accelerating resynthesis of phospholipids and suppressing the release of free fatty acids, stabilizing cell membranes, and reducing free radical generation. Numerous experimental stroke studies with citicoline have shown improved outcome and reduced infarct size in both ischemic and hemorrhagic stroke models. Citicoline has been studied worldwide in both ischemic and hemorrhagic clinical stroke with excellent safety and possibly efficacy found in several trials. A meta-analysis of four randomized US clinical citicoline trials concluded that treatment with oral citicoline within the first 24 h after a moderate to severe stroke is safe and increases the probability of complete recovery at 3 months. Citicoline clinical efficacy trials are now continuing outside of the US in both ischemic and hemorrhagic stroke. A citicoline supplement is now available from several sources on the internet.

AB - Citicoline (cytidine-5′-diphosphocholine or CDP-choline) is a precursor essential for the synthesis of phosphatidylcholine, one of the cell membrane components that is degraded during cerebral ischemia to free fatty acids and free radicals. Animal studies suggest that citicoline may protect cell membranes by accelerating resynthesis of phospholipids and suppressing the release of free fatty acids, stabilizing cell membranes, and reducing free radical generation. Numerous experimental stroke studies with citicoline have shown improved outcome and reduced infarct size in both ischemic and hemorrhagic stroke models. Citicoline has been studied worldwide in both ischemic and hemorrhagic clinical stroke with excellent safety and possibly efficacy found in several trials. A meta-analysis of four randomized US clinical citicoline trials concluded that treatment with oral citicoline within the first 24 h after a moderate to severe stroke is safe and increases the probability of complete recovery at 3 months. Citicoline clinical efficacy trials are now continuing outside of the US in both ischemic and hemorrhagic stroke. A citicoline supplement is now available from several sources on the internet.

KW - Acute stroke

KW - CDP-choline

KW - Citicoline

KW - Neuroprotection

KW - Stroke recovery

UR - http://www.scopus.com/inward/record.url?scp=67649579964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649579964&partnerID=8YFLogxK

U2 - 10.1517/14656560902765652

DO - 10.1517/14656560902765652

M3 - Article

C2 - 19351232

AN - SCOPUS:67649579964

VL - 10

SP - 839

EP - 846

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 5

ER -